Home/ Stocks/ DTIL

Precision BioSciences, Inc. Common Stock

DTIL XNAS

$7.49 +0.07 (+0.94%) ▲ 15-min delayed

Open

$7.47

High

$7.76

Low

$7.39

Volume

240.1K

Market Cap

$204.80M

About Precision BioSciences, Inc. Common Stock

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 66 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$10.84M	$-18,441,000	$-0.75
FY 2025	$34.26M	$-45,724,000	$-3.56
Q3 2025	$13.0K	$-21,772,000	$-1.84
Q2 2025	$18.0K	$-23,520,000	$-2.13

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 2, 2026

Calendar →

Related Market News

No specific coverage for DTIL yet. Check out our latest market news or earnings calendar.

Get DTIL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Precision BioSciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.